VJ

Vikas Jindal

Director Director DIN 07154566
DIN 07154566 First appointment May 2015 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2015
Shareholding value •••• Premium profile

About Vikas Jindal

Data last updated:

Vikas Jindal was a Director at Kunj Pharma Private Limited (2015–2018) and Director at Gemtech Pharmaceuticals Private Limited (2017–2018). The companies operate in Pharma and Business Services.

DIN 07154566
Primary Designation Director
Industry Pharma
First Appointment 01 May 2015

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kunj Pharma Private Limited U51397DL2015PTC279683
Director01 May 20152015₹5.46 Cr (FY 2025)Active
Director18 May 20172017Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Kunj Pharma Private Limited
Gemtech Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Vikas Jindal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vikas Jindal

Vikas Jindal was first appointed on 01 May 2015 as Director at Kunj Pharma Private Limited. The most recent appointment on record is 18 May 2017 at Gemtech Pharmaceuticals Private Limited.

Vikas Jindal held 2 earlier board appointments: Kunj Pharma Private Limited (Director, 01 May 2015 to 13 Apr 2018); Gemtech Pharmaceuticals Private Limited (Director, 18 May 2017 to 30 Apr 2018).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available